1. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of
chronic kidney disease. Lancet. 2010;375:1296–309.
2. Pani A, Bragg-Gresham J, Masala M, Piras D, Atzeni A, Pilia MG, et al.
Prevalence of CKD and its relationship to eGFR-related genetic loci and
clinical risk factors in the SardiNIA study cohort. J Am Soc Nephrol. 2014;25:
1533–44.
3. Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo
T, et al. Associations of kidney disease measures with mortality and endstage renal disease in individuals with and without hypertension: a metaanalysis. Lancet. 2012;380:1649–61.
4. Anand S, Shivashankar R, Ali MK, Kondal D, Binukumar B, Montez-Rath ME,
et al. Prevalence of chronic kidney disease in two major Indian cities and
projections for associated cardiovascular disease. Kidney Int. 2015;88:178–85.
5. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence
of chronic kidney disease in the United States. JAMA. 2007;298:2038–47.
6. Brück K, Stel VS, Gambaro G, Hallan S, Völzke H, Ärnlöv J, et al. CKD
prevalence varies across the European general population. J Am Soc
Nephrol. 2016;27:2135–47.
7. Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, et al. Analysis of the Global
Burden of Disease study highlights the global, regional, and national trends
of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int.
2018;94:567–81.
8. Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, et al.
Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol.
2009;20:223–8.
9. Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE. The severity of
acute kidney injury predicts progression to chronic kidney disease. Kidney
Int. 2011;79:1361–9.
10. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney
injury: a systematic review and meta-analysis. Kidney Int. 2012;81:442–8.
11. Vielhauer V, Berning E, Eis V, Kretzler M, Segerer S, Strutz F, et al. CCR1
blockade reduces interstitial inflammation and fibrosis in mice with
glomerulosclerosis and nephrotic syndrome. Kidney Int. 2004;66:2264–78.
12. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc
Nephrol. 2010;21:1819–34.
13. Fu Y, Tang C, Cai J, Chen G, Zhang D, Dong Z, et al. Rodent models of AKICKD transition. Am J Physiol Renal Physiol. 2018;315:F1098–106.
14. Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an
integrated clinical syndrome. Kidney Int. 2012;82:516–24.
15. Tanaka S, Tanaka T, Nangaku M. Hypoxia as a key player in the AKI-to-CKD
transition. Am J Physiol Renal Physiol. 2014;307:F1187–95.
16. Ferenbach DA, Bonventre JV. Mechanisms of maladaptive repair after AKI
leading to accelerated kidney ageing and CKD. Nat Rev Nephrol. 2015;11:
264–76.
17. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous
hMSCs improve myocardial infarction in mice because cells embolized in
lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem
Cell. 2009;5:54–63.
18. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, et al. Therapeutic benefit of
intravenous administration of bone marrow stromal cells after cerebral
ischemia in rats. Stroke. 2001;32:1005–11.
19. Karussis D, Kassis I, Kurkalli BG, Slavin S. Immunomodulation and
neuroprotection with mesenchymal bone marrow stem cells (MSCs): a
proposed treatment for multiple sclerosis and other neuroimmunological/
neurodegenerative diseases. J Neurol Sci. 2008;265:131–5.
20. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout
forebrain and cerebellum, and they differentiate into astrocytes after injection
into neonatal mouse brains. Proc Natl Acad Sci. 1999;96:10711–6.
21. Jiang W, Ma A, Wang T, Han K, Liu Y, Zhang Y, et al. Intravenous
transplantation of mesenchymal stem cells improves cardiac performance
after acute myocardial ischemia in female rats. Transpl Int. 2006;19:570–80.
22. Monsel A, Zhu YG, Gennai S, Hao Q, Liu J, Lee JW. Cell-based therapy for
acute organ injury: preclinical evidence and ongoing clinical trials using
mesenchymal stem cells. Anesthesiology. 2014;121:1099–121.
23. Kusuma GD, Carthew J, Lim R, Frith JE. Effect of the microenvironment on
mesenchymal stem cell paracrine signaling: opportunities to engineer the
therapeutic effect. Stem Cells Dev. 2017;26:617–31.
Ishiuchi et al. Stem Cell Research & Therapy
(2020) 11:130
24. Chang CP, Chio CC, Cheong CU, Chao CM, Cheng BC, Lin MT. Hypoxic
preconditioning enhances the therapeutic potential of the secretome from
cultured human mesenchymal stem cells in experimental traumatic brain
injury. Clin Sci (Lond). 2013;124:165–76.
25. Lee JH, Yoon YM, Lee SH. Hypoxic preconditioning promotes the
bioactivities of mesenchymal stem cells via the HIF-1α-GRP78-Akt Axis. Int J
Mol Sci. 2017;18:E1320.
26. Yoshida K, Nakashima A, Doi S, Ueno T, Okubo T, Kawano KI, et al. Serumfree medium enhances the immunosuppressive and antifibrotic abilities of
mesenchymal stem cells utilized in experimental renal fibrosis. Stem Cells
Transl Med. 2018;7:893–905.
27. Wang JW, Qiu YR, Fu Y, Liu J, He ZJ, Huang ZT. Transplantation with
hypoxia-preconditioned mesenchymal stem cells suppresses brain injury
caused by cardiac arrest-induced global cerebral ischemia in rats. J Neurosci
Res. 2017;95:2059–70.
28. Wang Z, Fang B, Tan Z, Zhang D, Ma H. Hypoxic preconditioning increases
the protective effect of bone marrow mesenchymal stem cells on spinal
cord ischemia/reperfusion injury. Mol Med Rep. 2016;13:1953–60.
29. Liu YY, Chiang CH, Hung SC, Chian CF, Tsai CL, Chen WC, et al. Hypoxiapreconditioned mesenchymal stem cells ameliorate ischemia/reperfusioninduced lung injury. PLoS One. 2017;12:e0187637.
30. Zhang W, Liu L, Huo Y, Yang Y, Wang Y. Hypoxia-pretreated human MSCs
attenuate acute kidney injury through enhanced angiogenic and
antioxidative capacities. Biomed Res Int. 2014;2014:462472.
31. Ueno T, Nakashima A, Doi S, Kawamoto T, Honda K, Yokoyama Y, et al.
Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by
suppressing inflammation and inhibiting TGF-β1 signaling. Kidney Int. 2013;
84:297–307.
32. Furuhashi K, Tsuboi N, Shimizu A, Katsuno T, Kim H, Saka Y, et al. Serumstarved adipose-derived stromal cells ameliorate crescentic GN by
promoting immunoregulatory macrophages. J Am Soc Nephrol. 2013;24:
587–603.
33. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the
response to hypoxic stress. Mol Cell. 2010;40:294–309.
34. Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood
Rev. 2013;27:41–53.
35. Hayashi M, Sakata M, Takeda T, Yamamoto T, Okamoto Y, Sawada K, et al.
Induction of glucose transporter 1 expression through hypoxia-inducible
factor 1alpha under hypoxic conditions in trophoblast-derived cells. J
Endocrinol. 2004;183:145–54.
36. Zhang Y, Nakano D, Guan Y, Hitomi H, Uemura A, Masaki T, et al. A sodiumglucose cotransporter 2 inhibitor attenuates renal capillary injury and
fibrosis by a vascular endothelial growth factor-dependent pathway after
renal injury in mice. Kidney Int. 2018;94:524–35.
37. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common
pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17:17–25.
38. Tanaka T, Matsumoto M, Inagi R, Miyata T, Kojima I, Ohse T, et al. Induction
of protective genes by cobalt ameliorates tubulointerstitial injury in the
progressive Thy1 nephritis. Kidney Int. 2005;68:2714–25.
39. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired
angiogenesis in the remnant kidney model: II. Vascular endothelial growth
factor administration reduces renal fibrosis and stabilizes renal function. J
Am Soc Nephrol. 2001;12:1448–57.
40. Yang J, Dai C, Liu Y. A novel mechanism by which hepatocyte growth
factor blocks tubular epithelial to mesenchymal transition. J Am Soc
Nephrol. 2005;16:68–78.
41. Tan R, Zhang X, Yang J, Li Y, Liu Y. Molecular basis for the cell type specific
induction of SnoN expression by hepatocyte growth factor. J Am Soc
Nephrol. 2007;18:2340–9.
42. Zhang Z, Yang C, Shen M, Yang M, Jin Z, Ding L, et al. Autophagy mediates
the beneficial effect of hypoxic preconditioning on bone marrow
mesenchymal stem cells for the therapy of myocardial infarction. Stem Cell
Res Ther. 2017;8:89.
43. Saad A, Zhu XY, Herrmann S, Hickson L, Tang H, Dietz AB, et al. Adiposederived mesenchymal stem cells from patients with atherosclerotic
renovascular disease have increased DNA damage and reduced angiogenesis
that can be modified by hypoxia. Stem Cell Res Ther. 2016;7:128.
44. Schive SW, Mirlashari MR, Hasvold G, Wang M, Josefsen D, Gullestad HP,
et al. Human adipose-derived mesenchymal stem cells respond to shortterm hypoxia by secreting factors beneficial for human islets in vitro and
potentiate antidiabetic effect in vivo. Cell Med. 2017;9:103–16.
Page 15 of 15
45. Schu S, Nosov M, O'Flynn L, Shaw G, Treacy O, Barry F, et al.
Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med.
2012;16:2094–103.
46. Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, Ashraf M. Preconditioning
enhances cell survival and differentiation of stem cells during
transplantation in infarcted myocardium. Cardiovasc Res. 2008;77:134–42.
47. Herrmann JL, Wang Y, Abarbanell AM, Weil BR, Tan J, Meldrum DR.
Preconditioning mesenchymal stem cells with transforming growth factoralpha improves mesenchymal stem cell-mediated cardioprotection. Shock.
2010;33:24–30.
48. Ferreira JR, Teixeira GQ, Santos SG, Barbosa MA, Almeida-Porada G, Gonçalves
RM. Mesenchymal stromal cell secretome: influencing therapeutic potential by
cellular pre-conditioning. Front Immunol. 2018;9:2837.
49. Rafei M, Birman E, Forner K, Galipeau J. Allogeneic mesenchymal stem cells
for treatment of experimental autoimmune encephalomyelitis. Mol Ther.
2009;17:1799–803.
50. Montespan F, Deschaseaux F, Sensébé L, Carosella ED, Rouas-Freiss N.
Osteodifferentiated mesenchymal stem cells from bone marrow and
adipose tissue express HLA-G and display immunomodulatory properties in
HLA-mismatched settings: implications in bone repair therapy. J Immunol
Res. 2014;2014:230346.
51. Avivar-Valderas A, Martín-Martín C, Ramírez C, Del Río B, Menta R,
Mancheño-Corvo P, et al. Dissecting allo-sensitization after local
administration of human allogeneic adipose mesenchymal stem cells in
perianal fistulas of Crohn’s disease patients. Front Immunol. 2019;10:1244.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
...
論文の公開元へ
